Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Prime Global opens new UK office

Med comms agency expands with Macclesfield, Cheshire site

- PMLiVE

Gilead chalks up trial success for new NASH drug

Phase II selonsertib data encouraging for liver disease with no approved therapies

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

- PMLiVE

Julie Adrian joins inVentiv Health Communications

She becomes managing director for Europe

- PMLiVE

Charting a course for expansion

David Meek on Ipsen's strategic pillars and hopes in oncology

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

- PMLiVE

Amgen wins European approval for Parsabiv

Follows FDA knock-back in August for the chronic kidney disease treatment

- PMLiVE

A rock and a hard place

When insurance companies exclude drugs from their coverage

- PMLiVE

greyhealth group appoints digital strategy director

Tom Griffiths takes on the newly-created role

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

Siemens’ healthcare unit to become standalone business

German technology firm plans to publicly list it as Siemens Healthineers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links